Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Daan Gene Co., Ltd. (002030.SZ)
Guangzhou, CN
Daan Gene Co., Ltd. specializes in the research, development, manufacturing, and commercialization of clinical diagnostic reagents and instruments. The company's extensive product portfolio encompasses advanced solutions such as fluorescence quantitative PCR products, time-resolved series diagnostics, enzyme-linked immunoassay (EIA) kits, various diagnostic instruments, and specialized scientific research services. Beyond product offerings, the company extends its expertise to provide comprehensive medical examination and health management services. These encompass a wide range of offerings, from genetic susceptibility gene testing and tumor marker analysis to crucial cervical cancer screening and general routine physical examinations, alongside other personalized health support. Established in 2001, the company was originally known as Da An Gene Co., Ltd. of Sun Yat-Sen University. It is presently headquartered in Guangzhou, located in the People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.46% | +10.28% | +22.28% | +12.20% | +7.76% | +18.79% | +16.64% | -43.41% | -70.09% | -43.81% | +537.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-11.2% Q1'26: -11.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+19.7% Q1'26: -275.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-58.3% Q1'26: -36.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-99.4% Q1'26: -66.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-12.6% ★ Q1'26: -6.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.2% ★ Q1'26: +6.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.24× Q1'26: -0.31× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.47B
est: 1.42B (+3.8%)
|
1.61B
est: 1.84B (-12.4%)
|
1.54B
est: 2.40B (-35.6%)
|
853.02M
est: 1.84B (-53.7%)
|
757.66M
est: 2.40B (-68.4%)
|
2.40B
2.40B – 2.40B
+0.0% YoY
|
752.87M
752.87M – 752.87M
-68.6% YoY
|
| EBITDA |
158.40M
est: 313.11M (-49.4%)
|
185.82M
est: 405.91M (-54.2%)
|
157.61M
est: 528.02M (-70.2%)
|
-374.26M
est: 5.22M (-7,275.7%)
|
-453.14M
est: 6.78M (-6,778.7%)
|
6.78M
6.78M – 6.78M
+0.0% YoY
|
2.13M
2.13M – 2.13M
-68.6% YoY
|
| EBIT |
102.62M
est: 100.32M (+2.3%)
|
122.08M
est: 130.06M (-6.1%)
|
81.80M
est: 169.19M (-51.7%)
|
-713.02M
est: -411.34M (-73.3%)
|
-752.80M
est: -535.09M (-40.7%)
|
-535.09M
-535.09M – -535.09M
+0.0% YoY
|
-168.17M
-168.17M – -168.17M
+68.6% YoY
|
| Net Income |
101.24M
est: 177.72M (-43.0%)
|
106.69M
est: 130.33M (-18.1%)
|
86.45M
est: 159.30M (-45.7%)
|
-925.17M
est: 130.58M (-808.5%)
|
-744.38M
est: 159.61M (-566.4%)
|
159.61M
159.61M – 159.61M
+0.0% YoY
|
224.89M
224.89M – 224.89M
+40.9% YoY
|
| SGA |
426.61M
est: 301.66M (+41.4%)
|
544.97M
est: 391.07M (+39.4%)
|
459.13M
est: 508.72M (-9.7%)
|
333.32M
est: 379.40M (-12.1%)
|
102.05M
est: 493.54M (-79.3%)
|
493.54M
493.54M – 493.54M
+0.0% YoY
|
155.11M
155.11M – 155.11M
-68.6% YoY
|
| EPS |
0.07
est: 0.13 (-43.0%)
|
0.08
est: 0.09 (-16.6%)
|
0.06
est: 0.11 (-45.0%)
|
-0.66
est: 0.09 (-809.9%)
|
-0.53
est: 0.11 (-566.4%)
|
0.11
0.11 – 0.11
+0.0% YoY
|
0.16
0.16 – 0.16
+40.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.01% | 56.5K | 0.59% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 31.9K | 0.49% |
| 3 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.01% | 1.25M | 0.07% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.00% | 31.2K | 0.65% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 43.5K | 0.19% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 127.0K | 0.39% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 91.9K | 0.29% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 26.8K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.9K | 0.48% |
| 10 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 104.9K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bin Zhang | Secretary | — | male |
| Chen Hong wei | GM & Vice Chairman | — | male |
| Hong Junan | Chief Engineer & Assistant GM | — | male |
| Huang Zhizheng | Deputy GM, CFO & Director | — | male |
| Jun Pan | Accounting Supervisor | — | — |
| Jun Zeng | Deputy GM & Secretary | — | male |
| Liang Zhi kun | Deputy GM & Director | — | male |
| Yang Wang | Deputy GM & Marketing Director | — | male |
| Zhang Wei Jie | Deputy GM & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002030.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
